Vanderbilt University School of Medicine Reports Findings in COVID-19 [TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial]

Press/Media

Period	25 Apr 2023

Media coverage

Title	Vanderbilt University School of Medicine Reports Findings in COVID-19 [TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial]
Media name/outlet	NewsRx COVID-19 Daily
Country/Territory	United States
Date	25/04/23
URL	metabase.moreover.com/noarticleurl?type=psh&lni=683C-32D1-JBSP-11CB-00000-00
Persons	George Diaz